Targets › SERPINF2
1 program from 1 company in 2 trials: 2 Phase 2; Neurology, Cardiovascular; next expected readout Nov 2026.
Serine protease inhibitor. The major targets of this inhibitor are plasmin and trypsin, but it also inactivates matriptase-3/TMPRSS7 and chymotrypsin. (UniProt, P08697)
Open in Phaseline: the race on SERPINF2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Translational Sciences | TS23 Monoclonal antibody to α2-antiplasmin | SERPINF2 | Phase 2 | Pulmonary Embolism; Ischemic Stroke | Nov 2026 |
Pulmonary Embolism (1) Ischemic Stroke (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.